Novo Nordisk | NVO - Betriebsergebnis

Aktienkurs
37.97
Täglich Wechseln
0.55 1.47%
Monatlich
-2.19%
Jährlich
-41.33%
Q2 Prognose
35.64




Betriebsergebnis Veränderung Datum
ANI Pharmaceuticals USD 29.13M 6.3M 2025-12
Aurora Cannabis CAD -35.79M 19.88M 2025-12
Bausch Health Companies USD 719M 2M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Canopy Growth CAD -12.66M 1.64M 2025-12
Corcept Therapeutics USD 4.49M 5.73M 2025-12
Drreddys Laboratories INR 14.33B 2.51B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Merck USD 6.24B 318M 2025-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Novartis USD 4.06B 437M 2025-12
Novo Nordisk DKK 32.38B 1.7B 2025-12
Novo Nordisk DKK 5.18B 33.61B 2025-06
Pacira USD 3.19M 9.96M 2025-12
Perrigo USD 84.4M 9M 2025-12
Phibro Animal Health USD 54.99M 2.36M 2025-12
Prestige Brands USD 82.49M 2.82M 2025-12
Sanofi EUR 1.7B 2.17B 2025-12
Supernus Pharmaceuticals USD 13.82M 74.01M 2025-12
Zoetis USD 835M 101M 2025-12